Buy Biocon; target of Rs 340: Sharekhan
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 340 in its research report dated November 16, 2022. Read More Top 100 Best Sellers
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 340 in its research report dated November 16, 2022. Read More Top 100 Best Sellers
Sharekhan is bullish on Abbott India has recommended buy rating on the stock with a target price of Rs 22,780 in its research report dated November 15, 2022. Read More Top 100 Best Sellers
The CBDT has found that several land owners had hidden their income from the transfer of land, as well inflated costs, to show reduced capital gains. Read More Top 100 Best Sellers
The country#39;s largest carmaker on Friday crossed the 3,500 car sales outlets mark, more than doubling it from 1,300 dealerships a decade ago. Top 100 Best Sellers Read More
The private sector lender said it has inked a memorandum of understanding (MOU) with JCB India, a leading manufacturer of earthmoving and construction equipment. Read More Top 100 Best Sellers
Emkay Global Financial recommended hold rating on Life Insurance Corporation of India with a target price of Rs 750 in its research report dated November 17, 2022. Top 100 Best Sellers Read More
In a world that faces multiple crises, India looks good on growth and its currency is not doing as badly the others. Top 100 Best Sellers Read More
In today’s edition of Moneycontrol Pro Panorama: G20 may be going off mandate, Sebi#39;s proposal for buybacks, Indian IT firms rank low in value chain, what inflation trend means for markets, and more Read More Top 100 Best Sellers
Aadit Palicha and Kaivalya Vohra are taking on e-commerce giants Amazon and Flipkart with their quick-commerce offering they built from their dining table Top 100 Best Sellers Read More
In Q2, the company’s consolidated loss narrowed to Rs 186.63 crore compared to Rs 204.44 crore loss registered in the same quarter last year Top 100 Best Sellers Read More